ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BLTE vs LGND // EV/EBITDA & P/E VALUATION

Belite Bio Inc (NASDAQ) VS. Ligand Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: BLTE 0 — LGND 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BLTE VS. LGND) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BLTE LGND SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -15.90% 3.00% -18.90 LGND /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 95.0x — TIE /valuation <GO>
Free Cash Flow Yield -0.61% 0.77% -1.38 LGND /fcf-yield <GO>
Operating Margin — 15.30% — TIE /operating-margins <GO>
Net Profit Margin — 46.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — 60.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.40 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 LGND /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.3 61.9 -11.60 LGND /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.07 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 42.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.23B $6.43B -$202.5M LGND /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BLTE REV LGND REV BLTE GROSS % LGND GROSS % BLTE FCF LGND FCF
FY 2025 $235.8M $268.1M — — -$37.1M $48.9M
FY 2024 $112.0M $167.1M — — -$29.4M $95.2M
FY 2023 $88.7M $131.3M — — -$29.8M $43.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BLTE // BETA —
LGND // BETA 1.07